Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The wave of analyst downgrades that began on October 7 is now being echoed in the options market. Option Care Health has attracted a sixth firm downgrade in two days, this time from UBS, and the put-call ratio has climbed to its most extreme reading in months. The stock trades at $31.05, up 37.5% over the past week, yet the consensus mean target is now $29.53, below the current price.
UBS analyst A.J. Rice cut OPCH to Neutral on October 9, lowering his target from $39 to $32.05. That follows five downgrades on October 7 alone, from Barrington Research, Jefferies, Citizens, JP Morgan, and William Blair. The consensus is now 10 holds and zero buys. The mean target of $29.53 sits below where the stock is trading today, an unusual configuration that gives the Street nowhere to go but sideways at best.
Jefferies raised its target from $28 to $32.05 when it downgraded. JP Morgan set a $33 target. UBS cut its target from $39 to $32.05. Despite the differing arithmetic, all three point to the same conclusion: the 37% rally has consumed whatever upside the analysts had on offer.
The put-call ratio hit 0.2083 on October 8. That is 3.05 standard deviations above its 20-day mean of 0.133. Three days ago, before the downgrades, the PCR was 0.136, in line with its prior-month range. The shift is sharp and recent. Protective put buying at this scale, more than three sigmas above the norm, suggests options traders are hedging against a reversal from the highs.
The 52-week PCR range runs from 0.031 to 0.866, so 0.21 is not extreme in absolute terms. But the rate of change is the point. The PCR roughly doubled in two sessions.
Despite the downgrade cascade, the lending market shows no sign of fresh short conviction building. Availability stands at 1,390% of shares already borrowed: roughly 14 shares available for every one currently lent out. That is loose by any measure. Short interest at 6.7% of the free float has actually fallen 3.3% over the past week, consistent with short covering as the stock rallied.
Cost to borrow is 0.50%, up 55% over the past week, but the level itself remains low. The week-on-week rise in CTB reflects the stock's sharp price move, not a genuine tightening of borrow supply. With availability this ample, the structural conditions for a short squeeze are not present.
The next earnings print is scheduled for October 29. The fundamental debate will come back into focus quickly. The bear case centres on the $55 million EBITDA headwind from the CID/Stelara situation, revenue of $1.35 billion that missed estimates in the last quarter, and a back-half EBITDA ramp that analysts describe as demanding. The bull case rests on durable long-term demand for home infusion, acute therapy growth, and management's stated confidence in a $480 million to $510 million full-year EBITDA range.
Wikipedia attention for OPCH registered a z-score of 5.65 against its own 90-day history as of September 22, reflecting the sharp rise in retail interest that preceded and accompanied the squeeze.
See the live data behind this article on ORTEX.
Open OPCH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
